US Patent 10828285 Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
Patent 10828285 was granted and assigned to ChemoCentryx on November, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 5 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 11 Apr, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
108282850
Date of Patent
November 10, 2020
0Patent Application Number
162268650
Date Filed
December 20, 2018
0Official Website
Patent Citations
Patent Citations Received
Patent Primary Examiner
Edits on 28 Oct, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Oct, 2022
Golden AI
Infobox
Patent Citations
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10828285 Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10828285
Date of patent
November 10, 2020
Patent application number
16226865
Date Filed
December 20, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 10828285 Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
